Effect of Vitamin D Supplementation in Young South African Children Hospitalized With Acute Lower Respiratory Infection
Primary Purpose
Acute Lower Respiratory Tract Infection, Pneumonia, Bronchiolitis
Status
Unknown status
Phase
Phase 4
Locations
South Africa
Study Type
Interventional
Intervention
Vitamin D
Sponsored by
About this trial
This is an interventional treatment trial for Acute Lower Respiratory Tract Infection focused on measuring vitamin D supplementation, pneumonia, bronchiolitis
Eligibility Criteria
Inclusion Criteria:
- All children age 1month - 5 yrs, admitted in the paediatric unit of Dr George Mukhari Hospital with an acute lower respiratory tract infection i.e. bronchiolitis and/ or pneumonia
Exclusion Criteria:
- Children whose caregivers decline participation in the study Children with co-morbid chronic respiratory condition(s) Children who have received vitamin D supplementation in the past 30 days
Sites / Locations
- Dr George Mukhari Academic Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Vitamin D
Placebo
Arm Description
Vitamin D 2 500 IU daily from enrolment until hospital discharge
Placebo
Outcomes
Primary Outcome Measures
Comparison of change from baseline in modified Respiratory Distress Assessment Instrument score at hospital discharge between vitamin D supplement and placebo groups.
The modified Respiratory Distress Assessment Instrument score, involves the measurement of the child's respiratory rate, assessment of the use of accessory muscles, the child's color, and auscultatory findings; each of these is given a score from 0 to 3. The higher the score the more severe the clinical condition. This scoring system has been validated in a number of scientific studies.
Secondary Outcome Measures
Comparison of duration of hospitalization between vitamin D supplementation and placebo groups.
The duration of hospital stay will be calculated from the day of admission to the day the child is assessed and deemed fit for discharge by the attending physician. All children at discharge will have a modified RDAI score of less than 3.
Full Information
NCT ID
NCT02054182
First Posted
January 18, 2014
Last Updated
February 2, 2014
Sponsor
University of Limpopo
1. Study Identification
Unique Protocol Identification Number
NCT02054182
Brief Title
Effect of Vitamin D Supplementation in Young South African Children Hospitalized With Acute Lower Respiratory Infection
Official Title
Effect of Vitamin D Supplementation in Young Children With Acute Lower Respiratory Tract Infection at Dr George Mukhari Academic Hospital, Pretoria, South Africa
Study Type
Interventional
2. Study Status
Record Verification Date
January 2014
Overall Recruitment Status
Unknown status
Study Start Date
February 2014 (undefined)
Primary Completion Date
November 2014 (Anticipated)
Study Completion Date
January 2015 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Limpopo
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine whether vitamin D supplements given to children aged 1 month to 5 years, hospitalized with acute lower respiratory tract infection will improve symptoms and reduce the duration of hospitalization.
Detailed Description
In a randomized, double blind placebo controlled interventional study, children aged 1 month to 5 years, who are admitted with acute lower respiratory tract infection (ALRTI) to Dr George Mukhari Academic Hospital will be enrolled. The children will randomized to receive 2500 IU of vitamin D or a placebo. It is intended to enrol 320 children, 160 to receive vitamin D and the other 160 to receive a placebo. This sample size was calculated at 80% power and 5% significance. The children will be enrolled within 24 hours of admission and the intervention (supplement or placebo) will be daily until the child is discharged fron the hospital.
The severity of ALRTI will be assessed using the modified Respiratory Distress Assessment Instrument (MRDAI) score. The thorough physical examination and classification of severity of the symptoms will be done at enrolment and daily until hospital discharge.
Blood samples for vitamin D and calcium concentrations will be assessed at enrolment, before the child is given the supplement or placebo.
The difference in the improvement in MRDAI score between the placebo and the supplement will be assessed by analysis of variance (ANOVA). Similarly the difference in duration of hospital stay between the two groups will also be analysed using ANOVA. The association between the vitamin D levels and the MRDAI score on admission will also be assessed and analysed using ANOVA.
All eligible children will be sequentially enrolled until the desired sample size is reached. A simple randomisation by means of computer generated numbers will be used to minimize selection bias. Both the study subjects and the investigators will be blinded to the allocation (treatment or placebo). The unblinding will be done only after the analysis has been completed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Lower Respiratory Tract Infection, Pneumonia, Bronchiolitis
Keywords
vitamin D supplementation, pneumonia, bronchiolitis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
320 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Vitamin D
Arm Type
Active Comparator
Arm Description
Vitamin D 2 500 IU daily from enrolment until hospital discharge
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo
Intervention Type
Drug
Intervention Name(s)
Vitamin D
Other Intervention Name(s)
Cholecalciferol
Intervention Description
Vitamin D 2 500 IU daily from enrolment (within 24 hours of hospitalization) until discharge from hospital
Primary Outcome Measure Information:
Title
Comparison of change from baseline in modified Respiratory Distress Assessment Instrument score at hospital discharge between vitamin D supplement and placebo groups.
Description
The modified Respiratory Distress Assessment Instrument score, involves the measurement of the child's respiratory rate, assessment of the use of accessory muscles, the child's color, and auscultatory findings; each of these is given a score from 0 to 3. The higher the score the more severe the clinical condition. This scoring system has been validated in a number of scientific studies.
Time Frame
Participants will be followed for the duration of hospital stay, an expected average of 7 days
Secondary Outcome Measure Information:
Title
Comparison of duration of hospitalization between vitamin D supplementation and placebo groups.
Description
The duration of hospital stay will be calculated from the day of admission to the day the child is assessed and deemed fit for discharge by the attending physician. All children at discharge will have a modified RDAI score of less than 3.
Time Frame
Participants will be followed for the duration of hospital stay, an expected average of 7 days
Other Pre-specified Outcome Measures:
Title
Assessment of correlation between vitamin D levels and modified Respiratory Distress Assessment Instrument score
Description
Blood for vitamin D levels will be obtained at enrolment and this will be used to assess whether a child is vitamin D deficient. Severity of ALRTI symptoms will also be assessed at enrolment using the modified RDAI. The correlation between vitamin D deficiency and severity of symptoms will be assessed.
Time Frame
On day 1, i.e. date of randomization
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Month
Maximum Age & Unit of Time
5 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
All children age 1month - 5 yrs, admitted in the paediatric unit of Dr George Mukhari Hospital with an acute lower respiratory tract infection i.e. bronchiolitis and/ or pneumonia
Exclusion Criteria:
Children whose caregivers decline participation in the study Children with co-morbid chronic respiratory condition(s) Children who have received vitamin D supplementation in the past 30 days
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Winter-Rose S Nkosi, MBChB
Phone
+27125214444
Email
czawr@webmail.co.za
First Name & Middle Initial & Last Name or Official Title & Degree
Nolwandle N Duma, MBChB
Phone
+27125214444
Email
nollyduma@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Siyazi Mda, MBChB, PhD
Organizational Affiliation
Univeristy of Limpopo, Medunsa Campus
Official's Role
Study Chair
Facility Information:
Facility Name
Dr George Mukhari Academic Hospital
City
Pretoria
State/Province
Gauteng
ZIP/Postal Code
0204
Country
South Africa
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Winter-Rose S Nkosi, MBChB
Phone
+27125214444
Email
czawr@webmail.co.za
First Name & Middle Initial & Last Name & Degree
Nolwandle N Duma, MBChB
Phone
+27125214444
Email
nollyduma@gmail.com
First Name & Middle Initial & Last Name & Degree
Winter-Rose S Nkosi, MBChB
12. IPD Sharing Statement
Learn more about this trial
Effect of Vitamin D Supplementation in Young South African Children Hospitalized With Acute Lower Respiratory Infection
We'll reach out to this number within 24 hrs